Medscape |
Ribociclib Effective in Younger Breast Cancer Patients Too
Medscape SAN ANTONIO — The CDK4/6 inhibitor ribociclib (Kisqali, Novartis) dramatically improves progression-free survival (PFS) when added to endocrine therapy in ovarian-suppressed younger patients with hormone receptor-positive (HR+), human epidermal ... For Breast Cancer Patients, Less Time on Hormonal Meds? SABCS: I-SPY 3-year pCR results are powerful predictor for breast cancer survival Acupuncture Dulls Pain from Drugs to Prevent Breast Ca Recurrence |
from Health - Google News http://ift.tt/2jqG6yM
EmoticonEmoticon